Bai Aotai (688177.SH): BAT2206 receives listing approval from the Health Sciences Authority in Singapore.

Zhtng Cijng APP News, Bai Aotai (688177.SH) announced that the company recently received the approval notice from the Health Sciences Authority of Singapore (HSA) for the listing of BAT2206 (ustekinumab injection). This drug is indicated for moderate to severe plaque psoriasis (PsO), moderate to severe active Crohn's disease (CD), etc. BAT2206 is the company's first product approved for listing by HSA, marking a further expansion of the company's overseas sales product matrix, continuous enhancement of international market competitiveness, and is expected to have a positive impact on the company's long-term business performance.